西马鲁肽对小鼠骨骼肌质量和发力能力的意外影响

IF 30.9 1区生物学 Q1 CELL BIOLOGY

Cell metabolism Pub Date : 2025-08-05 DOI:10.1016/j.cmet.2025.07.004

Takuya Karasawa, Ran Hee Choi, Cesar A. Meza, Subhasmita Rout, Micah J. Drummond, Amandine Chaix, Katsuhiko Funai

{"title":"西马鲁肽对小鼠骨骼肌质量和发力能力的意外影响","authors":"Takuya Karasawa, Ran Hee Choi, Cesar A. Meza, Subhasmita Rout, Micah J. Drummond, Amandine Chaix, Katsuhiko Funai","doi":"10.1016/j.cmet.2025.07.004","DOIUrl":null,"url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Main text</h2>Glucagon-like peptide-1 receptor (GLP-1R) agonists, such as semaglutide, represent a significant breakthrough in pharmacological interventions to treat obesity. Meanwhile, there have been recent concerns that GLP-1R agonist treatment leads to a loss of lean mass, potentially compromising physical functions and quality of life, particularly in those susceptible to sarcopenia. In the STEP-1 trial of semaglutide, lean mass was reduced by 6.92 kg with a weight reduction of 15.3 kg, indicating that</section></section><section><section><h2>Acknowledgments</h2>This work was supported by <span>NIH</span> grants DK107397, DK127979, GM144613, and AG074535 to K.F.; CA286584 and AG065993 to A.C.; and AG076075 and AG086328 to M.J.D. and the grant-in-aid for <span>Japan Society for Promotion of Science</span> (<span>JSPS</span>) Fellows 24KJ2039 to T.K.</section></section><section><section><h2>Author contributions</h2>T.K., R.H.C., M.J.D., A.C., and K.F. conceived the project and designed the experiments. T.K., R.H.C., and C.A.M. conducted the majority of experiments for this manuscript. S.R. assisted with tissue histological analyses. T.K. and K.F. wrote the manuscript. This manuscript was reviewed, revised, and given approval by all authors for publication. K.F. is the guarantor of this work and, as such, has full access to all the data in the study and takes responsibility for the integrity and the</section></section><section><section><h2>Declaration of interests</h2>The authors declare no competing interests.</section></section>","PeriodicalId":9840,"journal":{"name":"Cell metabolism","volume":"46 1","pages":""},"PeriodicalIF":30.9000,"publicationDate":"2025-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Unexpected effects of semaglutide on skeletal muscle mass and force-generating capacity in mice\",\"authors\":\"Takuya Karasawa, Ran Hee Choi, Cesar A. Meza, Subhasmita Rout, Micah J. Drummond, Amandine Chaix, Katsuhiko Funai\",\"doi\":\"10.1016/j.cmet.2025.07.004\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<h2>Section snippets</h2><section><section><h2>Main text</h2>Glucagon-like peptide-1 receptor (GLP-1R) agonists, such as semaglutide, represent a significant breakthrough in pharmacological interventions to treat obesity. Meanwhile, there have been recent concerns that GLP-1R agonist treatment leads to a loss of lean mass, potentially compromising physical functions and quality of life, particularly in those susceptible to sarcopenia. In the STEP-1 trial of semaglutide, lean mass was reduced by 6.92 kg with a weight reduction of 15.3 kg, indicating that</section></section><section><section><h2>Acknowledgments</h2>This work was supported by <span>NIH</span> grants DK107397, DK127979, GM144613, and AG074535 to K.F.; CA286584 and AG065993 to A.C.; and AG076075 and AG086328 to M.J.D. and the grant-in-aid for <span>Japan Society for Promotion of Science</span> (<span>JSPS</span>) Fellows 24KJ2039 to T.K.</section></section><section><section><h2>Author contributions</h2>T.K., R.H.C., M.J.D., A.C., and K.F. conceived the project and designed the experiments. T.K., R.H.C., and C.A.M. conducted the majority of experiments for this manuscript. S.R. assisted with tissue histological analyses. T.K. and K.F. wrote the manuscript. This manuscript was reviewed, revised, and given approval by all authors for publication. K.F. is the guarantor of this work and, as such, has full access to all the data in the study and takes responsibility for the integrity and the</section></section><section><section><h2>Declaration of interests</h2>The authors declare no competing interests.</section></section>\",\"PeriodicalId\":9840,\"journal\":{\"name\":\"Cell metabolism\",\"volume\":\"46 1\",\"pages\":\"\"},\"PeriodicalIF\":30.9000,\"publicationDate\":\"2025-08-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cell metabolism\",\"FirstCategoryId\":\"99\",\"ListUrlMain\":\"https://doi.org/10.1016/j.cmet.2025.07.004\",\"RegionNum\":1,\"RegionCategory\":\"生物学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CELL BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cell metabolism","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1016/j.cmet.2025.07.004","RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CELL BIOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

胰高血糖素样肽-1受体（GLP-1R）激动剂，如semaglutide，代表了药物干预治疗肥胖的重大突破。与此同时，最近有人担心GLP-1R激动剂治疗会导致瘦质量的损失，潜在地损害身体功能和生活质量，特别是对那些易患肌肉减少症的人。在semaglutide的STEP-1试验中，瘦质量减少了6.92 kg，体重减轻了15.3 kg，表明这项工作得到了NIH拨款DK107397， DK127979， GM144613和AG074535给kf的支持；CA286584和AG065993交流电；和AG076075和AG086328资助M.J.D.和日本科学促进会（JSPS）研究员24KJ2039资助t.k.。， r.h.c., m.j.d., a.c.和K.F.构思了这个项目并设计了实验。t.k., r.h.c.和C.A.M.为这份手稿做了大部分实验。S.R.协助组织组织学分析。T.K.和K.F.写了手稿。这篇手稿经过了所有作者的审查、修改和批准，才得以出版。K.F.是这项工作的担保人，因此，他可以完全访问研究中的所有数据，并对研究的完整性和利益声明负责。作者声明没有竞争利益。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Unexpected effects of semaglutide on skeletal muscle mass and force-generating capacity in mice

Section snippets

Main text

Glucagon-like peptide-1 receptor (GLP-1R) agonists, such as semaglutide, represent a significant breakthrough in pharmacological interventions to treat obesity. Meanwhile, there have been recent concerns that GLP-1R agonist treatment leads to a loss of lean mass, potentially compromising physical functions and quality of life, particularly in those susceptible to sarcopenia. In the STEP-1 trial of semaglutide, lean mass was reduced by 6.92 kg with a weight reduction of 15.3 kg, indicating that

Acknowledgments

This work was supported by NIH grants DK107397, DK127979, GM144613, and AG074535 to K.F.; CA286584 and AG065993 to A.C.; and AG076075 and AG086328 to M.J.D. and the grant-in-aid for Japan Society for Promotion of Science (JSPS) Fellows 24KJ2039 to T.K.

Author contributions

T.K., R.H.C., M.J.D., A.C., and K.F. conceived the project and designed the experiments. T.K., R.H.C., and C.A.M. conducted the majority of experiments for this manuscript. S.R. assisted with tissue histological analyses. T.K. and K.F. wrote the manuscript. This manuscript was reviewed, revised, and given approval by all authors for publication. K.F. is the guarantor of this work and, as such, has full access to all the data in the study and takes responsibility for the integrity and the

Declaration of interests

The authors declare no competing interests.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Cell metabolism 生物-内分泌学与代谢

CiteScore

48.60

自引率

1.40%

发文量

173

审稿时长

2.5 months

期刊介绍： Cell Metabolism is a top research journal established in 2005 that focuses on publishing original and impactful papers in the field of metabolic research.It covers a wide range of topics including diabetes, obesity, cardiovascular biology, aging and stress responses, circadian biology, and many others. Cell Metabolism aims to contribute to the advancement of metabolic research by providing a platform for the publication and dissemination of high-quality research and thought-provoking articles.